EU clears Hansen's Magellan robotic system

Justine Varieur Cadet | | Health Imaging | Screening
Hansen Medical, a developer of robotic technology for 3D control of catheter movement, announced July 26 that it has completed the European Union conformity assessment procedure and affixed a CE mark on its Magellan robotic system.

The Magellan robotic system is intended to facilitate navigation to anatomical targets in the peripheral vasculature and subsequently provide a conduit for manual placement of therapeutic devices, according to the Mountain View, Calif.-based company.

While the CE mark enables Hansen to commence a full launch of Magellan in the European Union, the company will commence commercialization at selected centers initially, with a full launch expected in the first half of 2012.

The Magellan system is designed for use with the NorthStar robotic catheter and related accessories, which have not yet received CE marks. Also, in the U.S., the Magellan robotic system does not have FDA clearance and is not commercially available. The company submitted a 510(k) pre-market notification application for the Magellan robotic system, the NorthStar robotic catheter and accessories to the FDA earlier this year.

Justine Varieur Cadet

Related Content

Abbreviated MRI protocols present suitable alternatives for liver cancer screening
Routine abdominal CTs offer insight into cardiovascular risk
Screening efforts have helped avert millions of cancer-related deaths in recent decades
What breast density status can tell us about cardiovascular risk
FDA clears AI tool that flags signs of heart disease in chest CT scans
Patients without PCPs struggle to access lung cancer screening, despite eligibility

Around the web

Radiology Business
AI can help radiology standardize image exam data labeling

To fully leverage today's radiology IT systems, standardization is a necessity. Steve Rankin, chief strategy officer for Enlitic, explains how artificial intelligence can help.

Radiology Business
The biggest obstacles facing radiology business managers in 2025

RBMA President Peter Moffatt discusses declining reimbursement rates, recruiting challenges and the role of artificial intelligence in transforming the industry.

Cardiovascular Business
New cardiac prevention paradigm explored in TRANSFORM trial using AI and CCTA

Deepak Bhatt, MD, director of the Mount Sinai Fuster Heart Hospital and principal investigator of the TRANSFORM trial, explains an emerging technique for cardiac screening: combining coronary CT angiography with artificial intelligence for plaque analysis to create an approach similar to mammography.